• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Technologies
    • Balloons
    • Brain-computer interfaces
    • Cardiac Implants
    • Catheters
    • Endoscopes
    • Heart valves
    • Pulsed Field Ablation
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Molding
      • Injection Molding
      • Insert molding
      • Mold Components
    • Tools
  • Materials
    • Advanced Materials
    • Metals
    • Nitinol
    • Plastics
    • Silicone
  • Business
    • Distribution Agreements
    • Legal News
    • Mergers & Acquisitions
    • Partnerships
    • Personnel Moves
  • Regulatory
    • 510(k)
    • CE Mark
    • FDA Breakthrough Designation
    • ISO Certification
    • Pre-Market Approval (PMA)
    • Recalls
  • Suppliers
  • About Us

J&J used RWE for expanded indications — and you can, too

August 18, 2023 By Jim Hammerand

Two J&J MedTech leaders shared advice to help medical device developers use real-world evidence (RWE) in FDA submissions.

A photo of the Biosense Webster ThermoCool SmartTouch ablation catheter.
J&J MedTech’s Biosense Webster ThermoCool SmartTouch [Image courtesy of J&J MedTech]
Real-world evidence (RWE) took a big step forward recently when the FDA approved expanded indications for Johnson & Johnson MedTech ablation catheters.

For the first time, the federal medical device safety regulator approved a label expansion based on RWE from a retrospective study of health records documenting off-label use by physicians.

“The clinical evidence used to support the expansion of indications was based solely on an analysis of a dataset comprised of electronic health records from two hospital systems,” the agency said. “The FDA worked closely with the study sponsor to ensure that the RWE resulting from the analysis was both relevant and reliable.”

A portrait of Anthony "Tony" Hong, VP of preclinical and clinical research and medical affairs for the cardiovascular and specialty solutions group at J&J MedTech.
Anthony “Tony” Hong is VP of preclinical and clinical research and medical affairs for the cardiovascular and specialty solutions group at J&J MedTech. [Photo courtesy of J&J MedTech]
Two J&J MedTech executives who led the project — Anthony “Tony” Hong, VP of preclinical and clinical research and medical affairs for the cardiovascular and specialty solutions group, and Paul Coplan, VP and global head of medical device epidemiology — discussed their experience to help other device developers use RWE in the same way.

The study was a test case for the National Evaluation System for Health Technology (NEST), which coordinated the FDA and J&J MedTech project to evaluate the use of RWE in regulatory decisions.

J&J MedTech won approval of one expanded indication after a six-month FDA review period, though this included a stop in the review clock for Mercy Health and Mayo Clinic, the research partners in the study, to reanalyze their data to address FDA’s additional data requests. It would normally take nine to 12 months for a traditional premarket approval (PMA) process, including investigational device exemption (IDE) review.

J&J MedTech’s Biosense Webster ThermoCool SmartTouch ablation catheter was already approved for paroxysmal atrial fibrillation (AFib), but cardiologists were also using the device to treat persistent AFib. The J&J MedTech team compared their device against another ablation catheter already approved for persistent AFib — the ThermoCool SmartTouch SF (STSF)— in an analysis of records for 1,450 patients treated with either of the devices at Mayo Clinic and Mercy Health.

RWE also secured expanded indications for both catheters and other devices to be used for ablation to treat AFib without fluoroscopy, sparing patients and physicians from potential X-ray radiation exposure.

A portrait of Paul Copland, VP and global head of medical device epidemiology at J&J MedTech.
Paul Coplan is VP and global head of medical device epidemiology at J&J MedTech. [Photo courtesy of J&J MedTech]
“There’s a lot of interest in using RWE more,” Coplan said. “The FDA has been particularly interested because there are often gaps in evidence, and sometimes I think that they see a medical need to get the label to be more consistent with what’s happening in clinical practice or what could be done to benefit patients. But they can’t get the evidence because it’s just too much of a hurdle to do a large clinical trial. So in that case, the RWE can actually help FDA, informing its public health role to provide patients and physicians with information that can guide the good practice of medicine.”

Read the whole conversation at Medical Design & Outsourcing.

Filed Under: Catheters, Regulatory, Uncategorized Tagged With: ablation, Biosense Webster, fda, johnson & johnson medtech

About Jim Hammerand

Jim Hammerand is the managing editor of Arrowfly's MassDevice and Medical Design & Outsourcing, where he leads coverage of medtech innovation, design, engineering and manufacturing. He also contributes to our Devicetalks podcasts and live events. Hammerand has more than two decades of journalism experience spanning newspapers, magazines, websites, live events, radio and TV news. For nearly a decade, Hammerand reported and edited business news for American City Business Journals as a reporter and digital editor at the Minneapolis/St. Paul Business Journal and then as managing editor of the Puget Sound Business Journal in Seattle. He holds degrees in journalism and management from the University of Minnesota and has won journalism awards from the Society of Professional Journalists, American Society of Business Publication Editors, and Trade, Association, Business Publications International. Connect with him on LinkedIn or by email at [email protected].

Primary Sidebar

“mte
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest trends and developments in medical tubing and extrusion.
MDO ad

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World
Drug Delivery Business News

Medical Tubing + Extrusion

Subscribe to our E-Newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | RSS